Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia? Homozygous familial hypercholesterolaemia is a rare and devastating autosomal co-dominant disorder affecting between one in 160 000 and 300 000 people in the general population.1 Homozygous familial h...

Linked Comment by Raul D Santos:
Does siRNA therapy against ANGPTL3 bring new hope in #homozygous #familial #hypercholesterolaemia? www.thelancet.com/journals/lan...
#zodasiran #HoFH #LDL #cholesterol

#MedSky #EndoSky #CardioSky

Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial Quarterly dosed zodasiran shows evidence of reductions in LDL cholesterol with a favourable safety profile, in patients with HoFH receiving background lipid-lowering therapy. Further investigation in ...

Quarterly dosed #zodasiran shows evidence of reductions in #LDL #cholesterol with a favourable safety profile, in patients with #HoFH receiving background lipid-lowering therapy www.thelancet.com/journals/lan...
#homozygous #familial #hypercholesterolaemia

#MedSky #EndoSky #CardioSky